Next 10 |
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymp...
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer PR Newswire SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, ...
2024-03-05 22:20:25 ET Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Conference Call March 5, 2024 4:30 AM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Offic...
2024-03-05 16:08:23 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: Gavreto Deal Expands Growth Prospects Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report Rigel Pharmaceuticals acquires U.S. rights to Gavreto ...
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net produ...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced t...
2024-02-23 08:30:00 ET Summary Rigel Pharmaceuticals reported promising preliminary Q4 and full-year 2023 results, with record-breaking net product sales for TAVALISSE and REZLIDHIA. The company's cash position remains healthy, providing support for its corporate, commercial, and ...
2024-01-08 12:44:41 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: Push To Profitability Continues, But COVID Beacon Seems Extinguished Rigel Pharmaceuticals, Inc. (RIGL) Q3 2023 Earnings Call Transcript Rigel Pharmaceuticals, Inc. 2023 Q3 - Results - Earnin...
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a collaboration with CONNEC...
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymp...
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer PR Newswire SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, ...
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net produ...